$QTRX News
Last published 2d ago
- 2d agoQTRXQuanterix Corp - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 2d agoQTRXQuanterix Releases Financial Results for the Third Quarter of 2026Business WireBILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced financial results for the third quarter ended September 30, 2026. “We delivered higher than expected topline growth in the third quarter, with revenues up 6.3% sequentially, despite continued market softness. This first step in restoring growth reflects sequentia ...
- 2d agoQTRXQuanterix Corporation Q3 2026 Earnings Call - QUANTERIX CORPEarnings Call TranscriptsHello everyone, thank you for joining us and welcome to Quantarix Corporation 3rd Quarter 2026 Earnings Call. After today's prepared remarks, you will host a question and answer session. If you would like to ask a questi
- 2w agoQTRXQuanterix To Report Third Quarter 2026 Financial Results on November 9, 2026Business WireQuanterix Corporation (NASDAQ:QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, November 9, 2026, at 8:30 AM ET, to discuss its third quarter 2026
- 1mo agoQTRXQuanterix and Innovita Expand IVD Access in China with National Medical Products Administration ApprovalsBusiness WireNMPA approvals for Quanterix SIMOA® instruments and key neurology biomarker assays advance access to ultra-sensitive blood-based testing in China Quanterix Corporation (NASDAQ:QTRX), a global leader in precision
- 1mo agoQTRXQuanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026Business WireMolecular Barcoding Kit Now Available Globally; TIME and high-plex ADC panels confirmed for Q4 shipment; Accelerator Laboratory Services open custom ADC panel development Quanterix Corporation (NASDAQ:QTRX) today
- 1mo agoQTRXQuanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireQuanterix Corporation (NASDAQ:QTRX), a global leader in precision biomarker science, today announced that on September 15, 2026, inducement grants (the "Inducement Grants") were made to James Gute, the recently
- 1mo agoQTRXQuanterix Names Dr. Yuri Fesko Chief Medical OfficerBusiness WireQuanterix Corporation (NASDAQ:QTRX), a global leader in precision biomarker science, today announced that accomplished physician executive Dr. Yuri Fesko has been appointed Chief Medical Officer of the company. In this
- 3mo agoQTRXCG 46TH ANNUAL GROWTH CONFERENCE - QUANTERIX CORPEarnings Call TranscriptsHi, welcome to the Canaccord Jury Growth Conference. I'm Kyle Mixon. I cover life science tools and diagnostics for Canaccord. Pleased to welcome you to this fireside chat with Quanterix. Here with us today, Quanterrix o
- 3mo agoQTRXCG 46TH ANNUAL GROWTH CONFERENCE - QUANTERIX CORPEarnings Call TranscriptsHi, welcome to the Canaccord Jury Growth Conference. I'm Kyle Mixon. I cover life science tools and diagnostics for Canaccord. Pleased to welcome you to this fireside chat with Quanterix. Here with us today, Quanterrix o
- 3mo agoQTRXQuanterix Corporation Q2 2026 Earnings Call - QUANTERIX CORPEarnings Call TranscriptsThank you for standing by. My name is Carly, and I will be your conference operator today. At this time, I would like to welcome everyone to the Quantarix Corporation Second Quarter 2026 Earnings Conference Call. All lin
- 3mo agoQTRXQuanterix Names Jim Gute Chief Commercial OfficerBusiness WireBrings 20 years of senior commercial leadership in healthcare and IT, including GE Healthcare and Exact Sciences Quanterix Corporation (NASDAQ:QTRX), a global leader in precision biomarker science, today announced
- 3mo agoQTRXQuanterix Releases Financial Results for the Second Quarter of 2026Business WireReports $32.9 million in revenue and $96.9 million of cash and marketable securities Company accelerating initiatives to drive commercial effectiveness Revises financial outlook for 2026 and extends date for
- 3mo agoQTRXQuanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12Business WireQuanterix Corporation (NASDAQ:QTRX), a global leader in precision biomarker science, today announced that senior management will participate in the Canaccord Genuity Capital Markets 46th Annual Growth Conference at the
- 3mo agoQTRXQuanterix To Report Second Quarter 2026 Financial Results on August 10, 2026Business WireQuanterix Corporation (NASDAQ:QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, August 10, 2026, at 8:30 AM ET, to discuss its second quarter 2026
- 3mo agoQTRXQuanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireQuanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a global leader in precision biomarker science, today announced that on July 15, 2026, an inducement grant (the "Inducement
- 4mo agoQTRXAnthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte AdvantagesBusiness WireBeginning July 1, 2026, Anthem Blue Cross and Blue Shield medical policies support eligible blood-based biomarker testing New peer-reviewed and AAIC data reinforce the clinical value of Quanterix's LucentAD®
- 4mo agoQTRXQuanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireQuanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on June 15, 2026,
- 5mo agoQTRXQuanterix Announces Appointment of Jason Faessler as Chief Financial OfficerBusiness WireQuanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Jason Faessler as the Company's new Chief
- 5mo agoQTRXQuanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of DiagnosticsBusiness WireStrategic Leadership Addition Signals Drive to Expand Diagnostics Business Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics,
- 5mo agoQTRXQuanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceBusiness WireQuanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that senior management will participate in the Goldman Sachs
- 5mo agoQTRXQuanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireQuanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on May 15, 2026, an
- 6mo agoQTRXQuanterix Announces Planned Transition of Chief Financial OfficerBusiness WireQuanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that Vandana Sriram, its Chief Financial Officer ("CFO") will
- 6mo agoQTRXQuanterix Releases Financial Results for the First Quarter of 2026Business WireReports $36.4 million in revenue and approximately $103 million of cash and marketable securities Company prioritizing product roadmap and investing in initiatives to drive commercial effectiveness Quanterix
- 6mo agoQTRXTEMLucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical WorkflowsBusiness WireAgreement supports the identification of patients eligible for Alzheimer's disease biomarker testing through Tempus Next and enables neurologists to order LucentAD® Complete on Tempus' clinical ordering
- 6mo agoQTRXQuanterix To Report First Quarter 2026 Financial Results on May 6, 2026Business WireQuanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Wednesday, May 6,
- 6mo agoQTRXAidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical OncologyBusiness WireNovel Assay, Developed on Akoya PhenoImager HT Platform with Opal Chemistry, Becomes First to Predict Both Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage Invasive Breast
- 7mo agoQTRXQuanterix Debuts Content Innovation Engine at AACR 2026Business WireThe Content Innovation Engine brings together Akoya's spatial biology platform and Quanterix's immunoassay infrastructure to systematically unlock cancer biology and accelerate the path toward clinical
- 7mo agoQTRXQuanterix Corporation Announces Date of 2026 Annual MeetingBusiness WireQuanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection (the "Company"), today announced that the Company's 2026 annual meeting of shareholders (the
- 8mo agoQTRXQuanterix Releases Financial Results for the Fourth Quarter and Full Year 2025Business WireReports $43.9 million in revenue and cash balance of $122 million Company expects to achieve cash flow breakeven during 2026 Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through
- 8mo agoQTRXLucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities NationwideBusiness WireCollaboration Aims to Expand Access to Early Detection of Potential Disease Marker Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ:QTRX), today announced a partnership with Life Line Screening (LLS), a
- 8mo agoQTRXQuanterix to Participate in Upcoming Investor ConferencesBusiness WireQuanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its executive leadership team will participate in the
- 8mo agoQTRXQuanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026Business WireQuanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Monday, March 2, 2026,
- 9mo agoQTRXQuanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer's Disease DetectionBusiness WireSubmission utilizes the comprehensive five-analyte panel and algorithm that formed the basis for Quanterix's LucentAD® Complete LDT Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by
- 9mo agoQTRXQuanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireQuanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on January 15, 2026,
- 10mo agoQTRXQuanterix Announces Landmark Nature Study Redefining Alzheimer's Disease Neuropathology PrevalenceBusiness WireSimoa p-Tau 217 Assay Enables Largest Population-Based Assessment (11,000+ Samples) Revealing Striking Age-Related Increase and Broad Treatment Eligibility Quanterix Corporation (NASDAQ:QTRX), a company transforming
- 11mo agoEXASIDYAILMNIR+6Quanterix Announces Board and Leadership Changes to Support Next Stage of GrowthBusiness WireAppoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company")
- 11mo agoQTRXQuanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis MonitoringBusiness WirePublication in the journal ‘Brain' confirms complementary roles of the biomarkers for predicting relapse and chronic disability progression in multiple sclerosis (MS) Simoa technology paired with an extensive
- 1y agoQTRXQuanterix Releases Financial Results for the Third Quarter of 2025Business WireQuanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the third quarter ended September 30,
- 1y agoQTRXQuanterix To Report Third Quarter 2025 Financial Results on November 10, 2025Business WireQuanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, November 10, 2025, at 4:30 p.m.
- 1y agoQTRXQuanterix Corp. vs Fujirebio Diagnostics, Inc. - AIA Trial, Institution DeniedUS Patent Trial and Appeal Board
- 1y agoQTRXQuanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory PermitBusiness WirePermit approval enables expanded research capabilities and underscores commitment to accuracy, reliability, and scientific excellence Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through
- 1y agoQTRXQuanterix Corporation (QTRX) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoQTRXQuanterix Releases Financial Results for the Second Quarter of 2025Business WireQuanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2025. "Through our
- 1y agoQTRXQuanterix To Report Second Quarter 2025 Financial Results on August 7, 2025Business WireQuanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Thursday, August 7, 2025, at 4:30 p.m. E.T.,
- 1y agoQTRXQuanterix Announces Cooperation Agreement with Kent Lake CapitalBusiness WireCompany and Kent Lake Capital Agree to Identify New Independent Board Member Company will Seek Shareholder Approval to De-Classify its Board of Directors Board of Directors to Adopt Majority Voting Standard in
- 1y agoQTRXQuanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAICBusiness WireCompany highlights expanded capabilities following Akoya Biosciences Acquisition and Simoa® technology included in more than 55 posters and oral presentations at the annual conference demonstrating its impact on
- 1y agoQTRXQuanterix Expands Reach with IVD and Large Reference LabsBusiness WireSimoa Technology Advances Earlier Disease Detection by Measuring Signature Biomarkers Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today
- 1y agoQTRXKent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence ShareholdersPR NewswireKent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the...
- 1y agoQTRXQuanterix to Present at Goldman Sachs Global Healthcare ConferenceBusiness WireQuanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the